Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PHAT 
Phathom Pharmaceuticals Inc (PHAT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: PHAT (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $21.38
1 Year Target Price $21.38
| 6 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 43.11% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 882.54M USD | Price to earnings Ratio - | 1Y Target Price 21.38 |
Price to earnings Ratio - | 1Y Target Price 21.38 | ||
Volume (30-day avg) 9 | Beta 0.45 | 52 Weeks Range 2.21 - 19.71 | Updated Date 08/28/2025 |
52 Weeks Range 2.21 - 19.71 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.67 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.91 | Actual -0.79 |
Profitability
Profit Margin -289.51% | Operating Margin (TTM) -151.7% |
Management Effectiveness
Return on Assets (TTM) -59.03% | Return on Equity (TTM) -3489% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 938936727 | Price to Sales(TTM) 7.74 |
Enterprise Value 938936727 | Price to Sales(TTM) 7.74 | ||
Enterprise Value to Revenue 8.23 | Enterprise Value to EBITDA -2.2 | Shares Outstanding 70943696 | Shares Floating 51190838 |
Shares Outstanding 70943696 | Shares Floating 51190838 | ||
Percent Insiders 4.2 | Percent Institutions 84.01 |
Upturn AI SWOT
Phathom Pharmaceuticals Inc
Company Overview
History and Background
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for gastrointestinal diseases and disorders. Founded in 2019, it is relatively new and focused on late-stage clinical development.
Core Business Areas
- Acid-Related Disorders: Phathom focuses on developing and commercializing therapies for acid-related disorders, specifically erosive esophagitis and related conditions linked to PPI (Proton Pump Inhibitor) use.
Leadership and Structure
The company has a management team with experience in pharmaceutical development and commercialization. The organizational structure reflects a focus on research and development, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Voquezna (vonoprazan): Voquezna is Phathom's primary product, indicated for the treatment of erosive esophagitis and related conditions. Market share data is still evolving as the product has recently launched. Competitors include traditional proton pump inhibitors (PPIs) such as omeprazole (Prilosec), lansoprazole (Prevacid), and pantoprazole (Protonix).
Market Dynamics
Industry Overview
The gastrointestinal pharmaceutical market is large and competitive, with significant unmet needs for improved therapies for acid-related disorders.
Positioning
Phathom is positioning itself as a provider of innovative solutions to overcome the limitations of traditional PPIs with Voquezna, offering potentially faster and more effective acid suppression.
Total Addressable Market (TAM)
The estimated TAM for acid-related disorders is substantial, in the billions of dollars globally. Phathom is aiming to capture a segment of this market with its differentiated product.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action of vonoprazan
- Potential for improved efficacy compared to PPIs
- Experienced management team
- FDA approved drug Voquezna
Weaknesses
- Limited commercial history
- Reliance on a single product
- Small company size
- High cash burn rate
- Must compete with established and low cost PPIs
Opportunities
- Expansion of indications for vonoprazan
- Partnerships and collaborations
- Geographic expansion
- Addressing unmet needs in acid-related disorders
Threats
- Competition from generic PPIs
- Regulatory hurdles
- Clinical trial failures
- Reimbursement challenges
- Adverse events of vonoprazan
Competitors and Market Share
Key Competitors
- TAP Pharmaceuticals (acquired by Takeda and Abbott)
- AstraZeneca (AZN)
- Takeda Pharmaceutical (TAK)
Competitive Landscape
Phathom faces competition from established pharmaceutical companies with well-known PPIs and established market presence. Its advantage lies in the potential for superior efficacy and a novel mechanism of action. Disadvantages include smaller size and limited commercial experience.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's recent founding and drug approval.
Future Projections: Future growth is dependent on the successful commercialization of Voquezna and potential expansion into new indications. Analyst projections vary, reflecting the uncertainty inherent in the pharmaceutical industry.
Recent Initiatives: Recent initiatives include expanding the sales force, conducting post-marketing studies, and exploring potential partnerships.
Summary
Phathom Pharmaceuticals is a high-risk, high-reward biopharmaceutical company with a focus on acid-related disorders. Voquezna offers a potential improvement over existing PPIs, but its commercial success is not guaranteed. The company faces competition from larger, more established players and needs to effectively manage its cash burn rate.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary. Financial data may not be real-time.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Phathom Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2019-10-25 | CEO, President & Director Mr. Steven L. Basta M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 427 | Website https://www.phathompharma.com |
Full time employees 427 | Website https://www.phathompharma.com | ||
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.